Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 Return on Equity

Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 posts a ROE of -244.91%. That is below the Healthcare sector average of 21.67%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near 21.67% is typical. Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's -244.91% is lower that level. That is roughly 1230.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -244.91%; use YoY and peer views to separate noise from signal.

Context for HROWL's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.67%), and (3) consistency with growth and profitability. This page covers the first two; Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's other metric pages and overview cover the third.

Judging Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -244.91% here, then scan peer and history charts to see if the gap is persistent.